A reproducible immunopotency assay to measure mesenchymal stromal cell-mediated T-cell suppression

Cytotherapy

Volumn 17, Issue 2, 2015, Pages 140-151

  Bloom, Debra D ^a   Centanni, John M ^a   Bhatia, Neehar ^b   Emler, Carol A ^b   Drier, Diana ^b   Leverson, Glen E ^a   McKenna, David H ^c   Gee, Adrian P ^d   Lindblad, Robert ^e   Hei, Derek J ^b   Hematti, Peiman ^a,f  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d TEXAS CHILDREN S HOSPITAL   (United States)

^e EMMES CORPORATION   (United States)

^f UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Mesenchymal stromal cells; PACT; Potency assay; T cell suppression

Indexed keywords

CD3 ANTIBODY; HLA DR ANTIGEN; ANTIBODY; CD28 ANTIGEN; CD3 ANTIGEN; MEMBRANE ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CELL SURFACE; CELL VIABILITY; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOASSAY; IMMUNOPOTENCY ASSAY; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STROMA CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PROCESS DEVELOPMENT; REPRODUCIBILITY; BONE MARROW CELL; CELL CULTURE; CELL PROLIFERATION; CYTOLOGY; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE ACTIVATION; MONONUCLEAR CELL; PROCEDURES;

ANTIBODIES; ANTIGENS, CD28; ANTIGENS, CD3; ANTIGENS, SURFACE; BONE MARROW CELLS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; HUMANS; IMMUNOASSAY; IMMUNOMODULATION; IMMUNOSUPPRESSION; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MESENCHYMAL STROMAL CELLS; REPRODUCIBILITY OF RESULTS;

EID: 84922538007     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2014.10.002     Document Type: Article

References (50)

1. Friedenstein A.J., Piatetzky S., Petrakova K.V. Osteogenesis in transplants of bone marrow cells. JEmbryol Exp Morphol 1966, 16:381-390.
2. Keating A. Mesenchymal stromal cells: new directions. Cell Stem Cell 2012, 10:709-716.
3. Horwitz E.M., Keating A. Nonhematopoietic mesenchymal stem cells: what are they?. Cytotherapy 2000, 2:387-388.
4. Javazon E.H., Beggs K.J., Flake A.W. Mesenchymal stem cells: paradoxes of passaging. Exp Hematol 2004, 32:414-425.
5. Hematti P. Mesenchymal stromal cells and fibroblasts: a case of mistaken identity?. Cytotherapy 2012, 14:516-521.
6. Haniffa M.A., Collin M.P., Buckley C.D., Dazzi F. Mesenchymal stem cells: the fibroblasts' new clothes?. Haematologica 2009, 94:258-263.
7. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. Cytotherapy 2006, 8:315-317.
8. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
9. Caplan A.I. Mesenchymal stem cells. JOrthop Res 1991, 9:641-650.
10. Phinney D.G., Sensebe L. Mesenchymal stromal cells: misconceptions and evolving concepts. Cytotherapy 2013, 15:140-145.
11. Dazzi F., Ramasamy R., Glennie S., Jones S.P., Roberts I. The role of mesenchymal stem cells in haemopoiesis. Blood Rev 2006, 20:161-171.
12. Keating A. How do mesenchymal stromal cells suppress T cells?. Cell Stem Cell 2008, 2:106-108.
13. Le Blanc K., Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol 2012, 12:383-396.
14. Nauta A.J., Fibbe W.E. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007, 10:3499-3506.
15. Kim J., Hematti P. Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Exp Hematol 2009, 37:1445-1453.
16. Horwitz E.M., Dominici M. How do mesenchymal stromal cells exert their therapeutic benefit?. Cytotherapy 2008, 10:771-774.
17. Stagg J., Galipeau J. Mechanisms of immune modulation by mesenchymal stromal cells and clinical translation. Curr Mol Med 2013, 13:856-867.
18. Ghannam S., Pene J., Torcy-Moquet G., Jorgensen C., Yssel H. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. JImmunol 2010, 185:302-312.
19. Ankrum J.A., Ong J.F., Karp J.M. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol 2014, 32:252-260.
20. Le Blanc K., Tammik C., Rosendahl K., Zetterberg E., Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003 Oct, 31:890-896.
21. Battiwalla M., Hematti P. Mesenchymal stem cells in hematopoietic stem cell transplantation. Cytotherapy 2009, 11:503-515.
22. Sharma R.R., Pollock K., Hubel A., McKenna D. Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices. Transfusion 2014, 54:1418-1437.
23. Prockop D.J., Brenner M., Fibbe W.E., Horwitz E., Le Blanc K., Phinney D.G., et al. Defining the risks of mesenchymal stromal cell therapy. Cytotherapy 2010 Sep, 12:576-578.
24. Phinney D.G. Functional heterogeneity of mesenchymal stem cells: implications for cell therapy. JCell Biochem 2012, 113:2806-2812.
25. Phinney D.G. Biochemical heterogeneity of mesenchymal stem cell populations: clues to their therapeutic efficacy. Cell Cycle 2007, 6:2884-2889.
26. Ho A.D., Wagner W., Franke W. Heterogeneity of mesenchymal stromal cell preparations. Cytotherapy 2008, 10:320-330.
27. Goodrich A.D., Hematti P. Mesenchymal stem cell therapies: the quest for fine-tuning. Exp Dermatol 2014, 23:632-633.
28. Ren J., Stroncek D.F., Zhao Y., Jin P., Castiello L., Civini S., et al. Intra-subject variability in human bone marrow stromal cell (BMSC) replicative senescence: molecular changes associated with BMSC senescence. Stem Cell Res 2013, 11:1060-1073.
29. Sabatino M., Ren J., David-Ocampo V., England L., McGann M., Tran M., et al. The establishment of a bank of stored clinical bone marrow stromal cell products. JTransl Med 2012, 10:23.
30. Wagner W., Ho A.D. Mesenchymal stem cell preparations-comparing apples and oranges. Stem Cell Rev 2007, 3:239-248.
31. Mendicino M., Bailey A.M., Wonnacott K., Puri R.K., Bauer S.R. MSC-Based Product Characterization for Clinical Trials: An FDA Perspective. Cell Stem Cell 2014, 14:141-145.
32. Waterman R.S., Tomchuck S.L., Henkle S.L., Betancourt A.M. Anew mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS One 2010, 5:e10088.
33. Romieu-Mourez R., Francois M., Boivin M.N., Bouchentouf M., Spaner D.E., Galipeau J. Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype. JImmunol 2009, 182:7963-7973.
34. Chinnadurai R., Copland I.B., Patel S.R., Galipeau J. IDO-independent suppression of T cell effector function by IFN-gamma-licensed human mesenchymal stromal cells. JImmunol 2014, 192:1491-1501.
35. Nemeth K. Mesenchymal stem cell therapy for immune-modulation: the donor, the recipient, and the drugs in-between. Exp Dermatol 2014, 23:625-628.
36. Krampera M., Galipeau J., Shi Y., Tarte K., Sensebe L. Immunological characterization of multipotent mesenchymal stromal cells-The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy 2013, 15:1054-1061.
37. Bianco P., Robey P.G., Simmons P.J. Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell 2008, 2:313-319.
38. Le Blanc K., Tammik L., Sundberg B., Haynesworth S.E., Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003, 57:11-20.
39. Viswanathan S., Keating A., Deans R., Hematti P., Prockop D., Stroncek D.F., et al. Soliciting Strategies for Developing Cell-Based Reference Materials to Advance MSC Research and Clinical Translation. Stem Cells Dev 2014, 23:1157-1167.
40. Hanley P.J., Mei Z., Durett A.G., da Graca Cabreira-Harrison M., Klis M., Li W., et al. Efficient manufacturing of therapeutic mesenchymal stromal cells with the use of the Quantum Cell Expansion System. Cytotherapy 2014, 16:1048-1058.
41. Wood D., Wesselschmidt R., Hematti P., Gee A.P., Rooney C., Silberstein L., et al. An Update from the United States National Heart, Lung, and Blood Institute-funded Production Assistance for Cellular Therapies (PACT) Program: A Decade of Cell Therapy. Clin Transl Sci 2014, 7:93-99.
42. Forbes G.M., Sturm M.J., Leong R.W., Sparrow M.P., Segarajasingam D., Cummins A.G., et al. Aphase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy. Clin Gastroenterol Hepatol 2014, 12:64-71.
43. Freedman M.S., Bar-Or A., Atkins H.L., Karussis D., Frassoni F., Lazarus H., et al. The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Mult Scler 2010, 16:503-510.
44. Wang D., Zhang H., Liang J., Li X., Feng X., Wang H., et al. Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience. Cell Transplant 2013, 22:2267-2277.
45. Trivedi P., Hematti P. Derivation and immunological characterization of mesenchymal stromal cells from human embryonic stem cells. Exp Hematol 2008, 36:350-359.
46. Le Blanc K., Rasmusson I., Gotherstrom C., Seidel C., Sundberg B., Sundin M., et al. Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scand J Immunol 2004, 60:307-315.
47. Galipeau J. The mesenchymal stromal cells dilemma-does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?. Cytotherapy 2013, 15:2-8.
48. Yin F., Battiwalla M., Ito S., Feng X., Chinian F., Melenhorst J.J., et al. Bone marrow mesenchymal stromal cells to treat tissue damage in allogeneic stem cell transplant recipients: correlation of biological markers with clinical responses. Stem Cells 2014, 32:1278-1288.
49. Lennon D.P., Schluchter M.D., Caplan A.I. The effect of extended first passage culture on the proliferation and differentiation of human marrow-derived mesenchymal stem cells. Stem Cells Transl Med 2012, 1:279-288.
50. Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105:1815-1822.